TEVA Q2 2023 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.9B+2.4% YoY

Gross Profit

$1.8B46.3% margin

Operating Income

-$654M-16.9% margin

Net Income

-$872M-22.5% margin

EPS (Diluted)

$-0.77

QoQ Revenue Growth

+5.9%

Cash Flow

Operating Cash Flow

$324M

Free Cash Flow

$205M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$43.1B

Total Liabilities

$35.4B

Stockholders' Equity

$7.1B

Cash & Equivalents

$2.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.9B	$3.8B	+2.4%
Gross Profit	$1.8B	$1.8B	+0.1%
Operating Income	-$654M	-$949M	+31.1%
Net Income	-$872M	-$232M	-275.9%

Revenue Segments

Product

$3.3B86%

Distribution Service

$402M10%

Product and Service, Other

$106M3%

License

$38M1%

Geographic Segments

North America Segment

$2.0B55%

Europe Segment

$1.2B32%

International Markets

$479M13%